Health Care & Life Sciences » Biotechnology | Editas Medicine Inc.

Editas Medicine Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2015
2016
2017
2018
Net Income before Extraordinaries
72,900.00
97,183.00
120,324.00
109,954
Depreciation, Depletion & Amortization
471.00
1,202.00
2,683.00
3,254
Other Funds
80.00
-
-
34,105
Funds from Operations
31,462.00
68,144.00
80,077.00
72,595
Changes in Working Capital
26,059.00
17,898.00
70,660.00
26,888
Net Operating Cash Flow
5,403.00
50,246.00
9,417.00
45,707
Capital Expenditures
1,431.00
3,493.00
2,059.00
Sale of Fixed Assets & Businesses
-
20.00
15.00
Purchase/Sale of Investments
-
-
181,766.00
Net Investing Cash Flow
1,431.00
3,473.00
183,810.00
Issuance/Reduction of Debt, Net
500.00
560.00
1,364.00
Net Financing Cash Flow
139,391.00
97,161.00
154,534.00
Net Change in Cash
132,557.00
43,442.00
38,693.00
Free Cash Flow
6,834.00
53,739.00
11,476.00
Change in Capital Stock
139,971.00
97,721.00
155,898.00

About Editas Medicine

View Profile
Address
11 Hurley Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.editasmedicine.com
Updated 07/08/2019
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A.